Either you do not have the newest version of Adobe Flash®, or you have JavaScript disabled.

Please ensure you have these capabilities.



RELEASES

  • For further information contact:
    Fred Iannotti
    802-888-0085
    fiannotti@planningsource.com

    Trimira Founding Scientist Calum MacAulay Creates Identafi Continuing Education Course

    Online One-Credit Course Teaches Use of "Multispectral" Technology

    HOUSTON, Jan. 29, 2010 — Head of the Cancer Imaging Department at British Columbia Cancer Research Center (BCCRC) Dr. Calum MacAulay has created an online one-hour continuing education course on Trimira® LLC's award-winning Identafi® 3000 ultra — the first and only oral cancer screening device to use a triple-wavelength fluorescence and reflectance optical system for early detection.

    Trimira® Continuing Education
    http://trimira.net/media/training

    The course, titled "Tissue Autofluorescence as An Aid in the Detection of Early Cancer and At-Risk Tissue," is offered through a partnership between BCCRC, an arm of the British Columbia Cancer Agency (BCCA), and Trimira® LLC, a privately held, Houston-based, medical diagnostic and imaging device company that has patented several cancer detection technologies, including the "multispectral" technology which minimizes false positives in oral tissue and reveals abnormalities missed by the naked eye.

    MacAulay's work focuses on research and development of new means for the detection, grading, and treatment of early, noninvasive cancer. He has helped develop devices that employ solid state sensors and advanced light sources, coupled with computer technology, to make previously invisible early cancers readily detectable.

    Dr. Calum MacAulay
    www.bccrc.ca/ci/people_cmacaula.html

    Targeting dentists, periodontists, oral surgeons, primary-care physicians, and otolaryngologists, the electronic course is accredited by Health Science Inc. The course instructs users in how to optimize Identafi® 3000 ultra's brilliant white, violet, and green-amber illumination. Created exclusively for intraoral use, the cordless Identafi® 3000 ultra is lightweight, portable, and ergonomically shaped. It incorporates a nickel-plated design that improves durability and delivers a smoother feel. The handheld is portable, and thus is readily moved from room to room and patient to patient.

    Identafi® 3000 ultra's spectroscopic technology is superbly effective in screening cancers in mucosal tissue. The same science works to help diagnose cervical, skin, gastrointestinal, and bladder cancers. Developed through the collaboration of three institutions — BCCRC, The University of Texas, and Rice University — Trimira® LLC's next-generation multispectral technology represents a quantum leap in the visualization of mucosal abnormalities, including cancer or premalignant dysplasia.

    Identafi® 3000 ultra delivers a higher degree of clinical accuracy and confidence to users, which translates into better patient care. Unlike other methods, Identafi® 3000 ultra pinpoints biochemical and morphological changes in cells. The device's violet wavelength capability was cited in the May 2009 issue of Cancer Prevention Research, the journal of the American Association for Cancer Research, as the best excitation wavelength to discriminate between neoplastic and non-neoplastic tissue areas.

    Identafi® 3000 Ultra
    www.trimira.net/identafi

    MacAulay's research interests and accomplishments include quantitative cytology and microscopy and fundamental work on tissue optical properties, including tissue fluorescence and ultrasound imaging.

    MacAulay is a clinical associate professor in pathology and laboratory medicine and an associate member in physics and astronomy at the University of British Columbia.

    In addition to MacAulay's academic appointments, he is a member of several scholarly societies, organizations, and editorial boards, including the British Columbia Science Council, by which he was recognized as Young Innovator of the Year (1999).

    One of three founding scientists at Trimira® LLC, he is also a member of Trimira® LLC's Scientific Advisory Board. An inventor and/or co-inventor in 18 granted patents and 35 pending patents, with numerous provisional patents recently filed, MacAulay is responsible for more than 200 peer-reviewed publications and 13 book chapters.

    About Trimira LLC

    Trimira® LLC is a private capital-funded company, with investment by Dallas cancer research philanthropist T. Boone Pickens, of oil and windfarming fame. Other Trimira® sister subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm®, as the parent company, has licensed exclusive use of certain of its patents and patents pending for use as a cervical cancer product to be later expanded to include additional epithelial-based cancers. Remicalm®'s core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.

    Visit Trimira® at: http://www.trimira.net/

Animations

Identafi® Technology



Identafi® 3000 ultra Process



Screening Results



Training